Sheikha S H, Collins T J, Rassoli A H, LeGate L S, Banerji T K
Life Sci. 1987 May 4;40(18):1835-44. doi: 10.1016/0024-3205(87)90095-6.
The purpose of the present study was to examine the effects of lithium, a drug which is now used rather widely in the treatment of acute mania and the prophylaxis of manic-depressive bipolar disorders, on the pituitary-gonadal function in the laboratory rat. Sexually adult male rats, maintained under standardized laboratory conditions (LD 14: 10; lights on at 06:00 h, CST), were injected (ip) with lithium chloride both acutely for 1 day and chronically for 5 days, and by utilizing a low and high dose. For the low dose, lithium was injected twice daily (at 10:00 and 15:00 h) at 2.5 meg/Kg for 1 and 5 days, whereas in the high dose groups, also receiving lithium twice daily and at the same hours, the dosages were 5 meq/Kg for 1 day and 3.5 meq/Kg for 5 days. Animals were sacrificed 4 hours after the last lithium (or saline) injections. Plasma and pituitary levels of luteinizing hormone (LH) and follicle stimulating hormone (FSH), and plasma levels of testosterone (T) were measured by radioimmunoassay (RIA). The administration of the low dose led to a significantly higher (P less than 0.001) plasma FSH, but unaltered plasma LH, levels after 5 days. In contrast, the high dose lithium led to significant suppressions of plasma LH (P less than 0.02; on day 5) and FSH (P less than 0.001; on both day 1 and 5) levels. The levels of plasma T also showed a significant reduction following the low dose (P less than 0.02; on day 5), as well as the high dose lithium treatment, as evident after both 1 (P less than 0.02) and 5 (P less than 0.02) days. Regardless of the dosage, or the duration of treatment, pituitary gonadotropin levels remained unaltered following lithium. The results of our present experiments suggest that lithium administration, either acutely or on a chronic basis, might be associated with significant adverse effects on the pituitary-testicular axis. Furthermore, since some of the hormonal changes were evident when plasma lithium concentration was within the therapeutic range, our data may have potential clinical implications.
本研究的目的是考察锂对实验大鼠垂体 - 性腺功能的影响,锂是一种目前广泛用于治疗急性躁狂症和预防躁狂 - 抑郁双相情感障碍的药物。性成熟雄性大鼠饲养于标准化实验室条件下(光照周期14小时光照:10小时黑暗,北京时间06:00开灯),分别进行为期1天的急性和为期5天的慢性腹腔注射氯化锂,设置低剂量和高剂量。低剂量组,每天两次(10:00和15:00)腹腔注射2.5毫当量/千克氯化锂,持续1天和5天;高剂量组同样每天两次在相同时间注射,剂量分别为1天5毫当量/千克和5天3.5毫当量/千克。在最后一次注射锂(或生理盐水)4小时后处死动物。采用放射免疫分析法(RIA)测定血浆和垂体中促黄体生成素(LH)、促卵泡生成素(FSH)水平以及血浆睾酮(T)水平。低剂量给药5天后导致血浆FSH水平显著升高(P < 0.001),但血浆LH水平未改变。相比之下,高剂量锂导致血浆LH水平(第5天,P < 0.02)和FSH水平(第1天和第5天,P < 0.001)显著降低。低剂量(第5天,P < 0.02)以及高剂量锂治疗后(第1天,P < 0.02;第5天,P < 0.02)血浆T水平也显著降低。无论剂量或治疗持续时间如何,锂处理后垂体促性腺激素水平均未改变。我们目前的实验结果表明,急性或慢性给予锂可能对垂体 - 睾丸轴产生显著的不良影响。此外,由于当血浆锂浓度在治疗范围内时一些激素变化就很明显,我们的数据可能具有潜在的临床意义。